TABLE 4.

Summary of TRAEs in the RD12014 and Victoza groups

MedDRA preferred term	RD12014 group (n = 49)	Victoza group (n = 49)	Total (n = 49)
Any AE	11 (22.4)	16 (32.7)	24 (49.0)
Number of events	14	19	33
Any TRAE	11 (22.4)	12 (24.5)	21 (42.9)
Number of events	13	12	25
Any SAE	0	0	0
AEs
Serum uric acid increased	3 (6.1)	3 (6.1)	6 (12.2)
Blood bilirubin increased	2 (4.1)	3 (6.1)	5 (10.2)
Blood triglyceride increased a	1 (2.0)	3 (6.1)	4 (8.2)
Blood glucose decreased	1 (2.0)	2 (4.1)	3 (6.1)
Upper respiratory tract infection b	0 (0)	2 (4.1)	2 (4.1)
Total bile acid increased	1 (2.0)	1 (2.0)	2 (4.1)
Conjugated bilirubin increased	2 (4.1)	0 (0)	2 (4.1)
Alanine aminotransferase increased	1 (2.0)	0 (0)	1 (2.0)
Neutrophil count increased	0 (0)	1 (2.0)	1 (2.0)
Aspartate aminotransferase increased	1 (2.0)	0 (0)	1 (2.0)
Vomit a	0 (0)	1 (2.0)	1 (2.0)
Nausea a	0 (0)	1 (2.0)	1 (2.0)
Diarrhea	1 (2.0)	0 (0)	1 (2.0)
Abdominal distention	1 (2.0)	0 (0)	1 (2.0)
Fever	0 (0)	1 (2.0)	1 (2.0)
Hematuria a	0 (0)	1 (2.0)	1 (2.0)

Note: Data are presented as number of subjects (%).

Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event.

^a AEs were not considered treatment‐related.

^b One of the upper respiratory tract infections was not considered treatment‐related.